Paraphrasing Donald Rumsfeld's now-infamous statement "There are known knowns […] . There are known unknowns.
[…] But there are also unknown unknowns," it seems that such a convoluted position applies equally well to MS, given its complex pathobiology. While we agree that inflammation is the classic "known known," to this date we do not have a clear understanding of what instigates the inflammatory response in the first place: a "known unknown." Indeed, all evidence, as mentioned by both sides of the current debate, is equally consistent with an "outside-in" versus "inside-out" pathogenesis. 1 As a result, and given the large body of work done on understanding the immunobiology of MS and the immunotherapeutics that sprang from these insights, Garber and Barnett's argument in favor of shifting gears toward improved therapies targeting degeneration and repair has merit.
However, 't Hart and Weissert point to the strong effect of major histocompatibility complex (MHC) class II and a near-universal adaptive T cell response in all phases of MS, as evidence of an important pathogenic role of the immune system. We do not disagree, but would point to rheumatic heart disease as an example of a chronic T cell-driven disorder; here, the most serious clinical sequelae are clearly due to autoimmune inflammation, but the primary cause is group A streptococcus bacteria and the exotoxins they shed, coupled with the destructive secondary host immune response. 2 The reference to the ORATORIO trial which used the B cell depletor ocrelizumab as evidence for inflammation driving progression has its caveat. In this trial, 26% of patients showed Gd-enhancing lesions, indicative of ongoing AS Al Sultan and PK Stys inflammation. Because the frequency of enhancing lesions in primary-progressive multiple sclerosis (PPMS) is variable and changes with time, 3 whether the proportion in the ORATORIO trial was atypically high or not is less important than the fact that significant inflammation was present. Therefore, we still do not know if B cell depletion is effective in progressive disease in the absence of measurable inflammation. Perhaps, the most insightful experiment shedding light on whether inflammation drives progression comes from autologous hematopoietic stem cell transplantation, where the immune system undergoes a major reset. The results are enlightening: in early highly active inflammatory disease, a majority of transplanted patients are not only cured of inflammation, but remain free of progression even after many years. 4 Equally interesting is the observation that the vast majority of secondary-progressive multiple sclerosis (SPMS) patients enjoy little benefit and continue to progress. 5 Taken together, we believe the adage "no inflammation, no benefit" related to disability progression with immune-modulating therapies continues to apply. These observations also support the notion that inflammation can promote disability progression, but that progression can also run independently of inflammation, likely due an underlying primary degenerative process.
While Garber and Barnett provide cogent arguments in favor of an underlying degenerative process, the obvious limitation is our collective lack of insight into what these fundamental mechanisms may be. The degenerative triggers of MS are no more clear than the causative antigens promoting autoimmunity. In the end, what seems clear is that the intertwined autoimmune inflammation and degeneration run in parallel in all MS patients, but their respective intensities may be greatly mismatched (e.g. the aggressive inflammatory relapsing-remitting multiple sclerosis (RRMS) patient who is "cured" after transplantation must have a much more benign degenerative underlay versus the late-onset rapidly progressive patient with minimal inflammation must harbor little dysimmunity). Importantly, there remains a perplexing "unknown unknown," the fundamental trigger of degeneration and concomitant inflammation, which should receive increased attention, and once better understood, will guide more effective therapies for all phases of this complex disease.
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